NVCT at a glance
Nuvectis Pharma, Inc. (NVCT, SEC CIK 1875558) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as August 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 17 institutional investment managers tracked by SignalX reported holding Nuvectis Pharma, Inc. (NVCT) shares worth $68.0 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Mosseri Marlio Charles on June 30, 2026 of 50,000 shares at $18.32 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 17 funds
- $68.0M · +0 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- New risk: U.S. trade-policy changes affecting China-originated NXP100 and NXP200 materials, technology, and clinical data
- New risk: Tariffs could increase research costs, although no tariffs affected operations as of September 30, 2026
- Regulatory risk: One Big Beautiful Bill Act FDA workforce reductions could delay product approvals
- Operational risk: Dependence on Haisco for NXP100 and NXP200 technology transfer and material supply
- Financial risk: Accumulated deficit reached $142.8 million through September 30, 2026, requiring substantial additional funding
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product revenue since inception
- Net loss $30.1M vs $7.5M YoY, operating loss $31.0M vs $7.8M
- Worst performer: NXP100, NXP200 and NXP900 development drove R&D $27.4M vs $5.8M
- Cash $140.7M, operating cash use $36.3M, financing cash inflow $145.4M
- Outlook: cash expected to fund operations through at least 12 months, additional capital required long term
AI summary of the NVCT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026
- Exhibit 99.1 contains the substantive results and management update for investor review
Item EX-99.1: Item EX-99.1
- Third-quarter 2026 results reflect major pipeline expansion, with China approval for ciprocopan and $140.7M cash extending runway into 2H 2029
- Ciprocopan’s U.S. path remains the key catalyst, with FDA discussions underway and an update expected before year-end
Item 8.01: Other Events
- New ATM program enables Nuvectis to sell common shares opportunistically through Jefferies
- $200 million shelf registration expands potential financing capacity across securities
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results and corporate update announced for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the substantive financial and operating details
Item EX-99.1: Item EX-99.1
- Q2 net loss $7.0M versus $6.3M; R&D rose to $4.7M from $3.6M as development activity accelerated
- July follow-on offering raised $115M gross, extending stated cash runway into 1H 2029 but increasing share dilution risk
AI summaries of NVCT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NVCT
Don't miss the next NVCT filing
- Alerts as it files. A push when NVCT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NVCT, by share count.
- Ask anything. An AI agent that reads every NVCT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Carson Michael J. | A | Aug 3, 2026 | 30,000 | - |
| Mosseri Marlio Charles | Buy | Jun 30, 2026 | 50,000 | $18.32 |
| BENTSUR RON | Buy | Jun 30, 2026 | 12,500 | $20.00 |
| Sanchez Juan | A | Jun 11, 2026 | 35,000 | - |
| Hoberman Kenneth | A | Jun 11, 2026 | 35,000 | - |
| Kaplan Matthew L. | A | Jun 11, 2026 | 35,000 | - |
| Oliviero James F III | A | Jun 11, 2026 | 35,000 | - |
| BENTSUR RON | A | Jan 6, 2026 | 150,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$22.9M | -$19.8M | -$27.6M | |
| Net Income | -$22.3M | -$19.0M | -$26.4M | |
| Balance Sheet | ||||
| Total Assets | $19.2M | $18.6M | $31.7M | |
| Equity | $12.2M | $9.7M | $18.4M | |
| ROE | -182.4% | -195.6% | -143.6% | |
| Per Share | ||||
| EPS | $-1.43 | $-1.11 | $-1.32 | |
| Cash Flow | ||||
| Operating CF | -$16.0M | -$12.2M | -$16.0M | |
Source: XBRL data in Nuvectis Pharma, Inc. (NVCT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate NVCT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 17 | $68.0M |
| Q2 2026 | 17 | $49.3M |
| Q1 2026 | 16 | $15.7M |
| Q4 2025 | 14 | $16.0M |
| Q3 2025 | 16 | $11.4M |
| Q2 2025 | 16 | $13.0M |
| Q1 2025 | 10 | $7.7M |
| Q4 2024 | 5 | $2.3M |
- BlackRock+305.7K (+31%)
- State Street Corp+120.8K (+49%)
- Vanguard Capital Management LLC+34.8K (+4%)
- Vanguard Portfolio Management LLC+27.6K (+23%)
- Northern Trust+24.4K (+17%)
- Citadel Advisors LLC−71.6K (-62%)
- Wells Fargo & Co−9.2K (-59%)
- Citigroup−7.0K (-87%)
- Morgan Stanley−3.8K (-20%)
- Invesco Ltd+89.3K
- FMR LLC (Fidelity)−8.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 111 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NVCT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Aug 21, 2026 | - | Analysis | - |
| SC 13G | Aug 6, 2026 | - | - | |
| 4 | Aug 5, 2026 | - | - | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jul 1, 2026 | - | - | - |
| 8-K | Jun 30, 2026 | - | Analysis | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-K | Feb 11, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 11, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - | |
| 4 | Jan 9, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
NVCT SEC filings: frequently asked questions
Which institutions hold NVCT stock?
As of September 30, 2026, the largest Nuvectis Pharma, Inc. (NVCT) holders among the 13F filers tracked by SignalX were BlackRock ($27.6 million), Vanguard Capital Management LLC ($19.2 million), State Street Corp ($7.8 million), Northern Trust ($3.6 million), Vanguard Portfolio Management LLC ($3.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did NVCT report in its latest 8-K?
Nuvectis Pharma, Inc. (NVCT) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results and corporate update announced for quarter ended September 30, 2026.
What are the latest NVCT SEC filings?
Nuvectis Pharma, Inc. (NVCT) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on August 5, 2026.
What is NVCT's SEC CIK number?
Nuvectis Pharma, Inc. (NVCT)'s SEC Central Index Key (CIK) is 1875558. EDGAR lists every NVCT filing under that number.
Ask anything about NVCT
The research agent reads NVCT's filings, financials, insider trades and 13F holders, then answers with sources.